Roivant Sciences News

ROIVWDelisted Stock  USD 2.68  0.36  11.84%   
Slightly above 62% of Roivant Sciences' investor base is looking to short. The analysis of current outlook of investing in Roivant Sciences suggests that many traders are alarmed regarding Roivant Sciences' prospects. Roivant Sciences' investing sentiment can be driven by a variety of factors including economic data, Roivant Sciences' earnings reports, geopolitical events, and overall market trends.
  
over a year ago at news.google.com         
Roivant Sciences Chief Operating Officer Acquires 195,166 Shares After Exercising Company Stock Opti...
Google News at Macroaxis
over a year ago at benzinga.com         
Roivant Announces Redemption of Outstanding Warrants
benzinga news
over a year ago at news.google.com         
Arbutus Biopharma Corporation has caught the attention of institutional investors who hold a sizeabl...
Google News at Macroaxis
over a year ago at news.google.com         
Ramaswamy Investments Seem at Odds With His Position on Woke Culture - Yahoo News
Google News at Macroaxis
over a year ago at news.google.com         
Roivant Sciences 7 billion bowel drug draws major pharma interest ... - Investing.com
Google News at Macroaxis
over a year ago at news.google.com         
Andreas Halvorsens Firm Curbs Roivant Sciences Stake - Forbes
Google News at Macroaxis
over a year ago at news.google.com         
Analysts Just Made A Significant Upgrade To Their Roivant Sciences Ltd. Forecasts - Yahoo Finance
Google News at Macroaxis
over a year ago at benzinga.com         
Nasdaq, SP 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results Why This Analyst Rates ...
benzinga news
over a year ago at news.google.com         
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and...
Google News at Macroaxis
over a year ago at benzinga.com         
Roivant to Host Investor Call at 800 AM ET on Thursday, June 22 to Review Results from the Chronic P...
benzinga news
over a year ago at news.google.com         
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial ...
Google News at Macroaxis
over a year ago at news.google.com         
Roivant Sciences Chief Accounting Officer Acquires 77736 Shares ... - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Investors in Sportradar Group have unfortunately lost 19 percent over the last year - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Roivants Vtama Meets Key Endpoints in Atopic Dermatitis Study ROIV - MarketWatch
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Roivant Sciences that are available to investors today. That information is available publicly through Roivant media outlets and privately through word of mouth or via Roivant internal channels. However, regardless of the origin, that massive amount of Roivant data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Roivant Sciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Roivant Sciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Roivant Sciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Roivant Sciences alpha.

Roivant Sciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Roivant to Host Investor Call at 800 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-310...
06/21/2023
2
Analysts Just Made A Significant Upgrade To Their Roivant Sciences Ltd. Forecasts - Yahoo Finance
06/29/2023
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in Roivant Stock

If you are still planning to invest in Roivant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Roivant Sciences' history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Content Syndication
Quickly integrate customizable finance content to your own investment portal